We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

14 hedge funds and large institutions have $2.25M invested in Protara Therapeutics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.54% less ownership

Funds ownership: 1.12% → 0.58% (-0.54%)

48% less funds holding

Funds holding: 27 → 14 (-13)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

76% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 17

89% less capital invested

Capital invested by funds: $19.6M → $2.25M (-$17.3M)

Holders
14
Holders Change
-13
Holders Change %
-48.15%
% of All Funds
0.3%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
4
Increased
3
Reduced
1
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$391K
2
WS
Wedbush Securities
California
+$168K
3
TSS
Two Sigma Securities
New York
+$145K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$45.1K
5
RJFSA
Raymond James Financial Services Advisors
Florida
+$32.9K

Top Sellers

1
NLVP
New Leaf Venture Partners
New York
-$3.46M
2
RCM
RA Capital Management
Massachusetts
-$3.04M
3
MAM
MPM Asset Management
Massachusetts
-$2.23M
4
BBA
Baker Bros. Advisors
New York
-$678K
5
BFM
Boothbay Fund Management
New York
-$246K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$1.01M – – –
DM
2
Deerfield Management
New York
$616K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$229K +$391K +3,429 +43%
DVC
4
Deer VII & Co
New York
$158K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$118K +$45.1K +395 +7%
WS
6
Wedbush Securities
California
$30K +$168K +1,475 New
TSS
7
Two Sigma Securities
New York
$26K +$145K +1,270 New
BlackRock
8
BlackRock
New York
$19K +$16.8K +147 +19%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$16K – – –
Northern Trust
10
Northern Trust
Illinois
$9K – – –
RJFSA
11
Raymond James Financial Services Advisors
Florida
$6K +$32.9K +288 New
Morgan Stanley
12
Morgan Stanley
New York
$5K -$94.6K -829 -77%
Mariner
13
Mariner
Kansas
$5K – – –
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.01K +$5.7K +50 New
NLVP
15
New Leaf Venture Partners
New York
– -$3.46M -38,080 Closed
RCM
16
RA Capital Management
Massachusetts
– -$3.04M -33,437 Closed
MAM
17
MPM Asset Management
Massachusetts
– -$2.23M -24,585 Closed
BBA
18
Baker Bros. Advisors
New York
– -$678K -7,465 Closed
BFM
19
Boothbay Fund Management
New York
– -$246K -2,707 Closed
FCI
20
Financial Counselors Inc
Kansas
– -$114K -1,250 Closed
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
– -$73K -802 Closed
RWM
22
Ritholtz Wealth Management
New York
– -$68K -750 Closed
PAM
23
Panagora Asset Management
Massachusetts
– -$30K -334 Closed
TAM
24
Tiverton Asset Management
Delaware
– -$30K -325 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$10K -110 Closed
1
2

TARA Hedge Fund Activity: Q1 2019 in Review

14 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2019, worth a combined $2.25M — down 89% from $19.6M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TARA and 4 opened new positions — a net loss of 13 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $391K. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $3.46M sold.

  • 14 institutional investors held Protara Therapeutics (TARA) as of Q1 2019, down from 27 in Q4 2018.
  • Funds reported $2.25M of Protara Therapeutics stock for Q1 2019, down 89% quarter-over-quarter.
  • 4 funds opened new Protara Therapeutics positions in Q1 2019 and 17 closed out, a net change of -13 holders.
  • The largest Protara Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $391K added.
  • The largest Protara Therapeutics seller in Q1 2019 was New Leaf Venture Partners, an estimated $3.46M sold.

Based on aggregated 13F filings for Q1 2019.